Last Updated: November 8, 2026

Details for New Drug Application (NDA): 021342

NDA 021342 describes LEVO-T, which is a drug marketed by Cediprof Inc and is included in one NDA. It is available from seven suppliers. Additional details are available on the LEVO-T profile page.

The generic ingredient in LEVO-T is levothyroxine sodium. There is one drug master file entry for this compound. Fifty suppliers are listed for this compound. Additional details are available on the levothyroxine sodium profile page.

Summary for 021342

Tradename:	LEVO-T
Applicant:	Cediprof Inc
Ingredient:	levothyroxine sodium
Patents:	0

Suppliers and Packaging for NDA: 021342

Tradename	Generic Name	Dosage	NDA	Application Type	Supplier	National Drug Code	Package Code	Package
LEVO-T	levothyroxine sodium	TABLET;ORAL	021342	NDA AUTHORIZED GENERIC	Lannett Company, Inc	0527-3280	0527-3280-43	1000 TABLET in 1 BOTTLE (0527-3280-43)
LEVO-T	levothyroxine sodium	TABLET;ORAL	021342	NDA AUTHORIZED GENERIC	Lannett Company, Inc	0527-3280	0527-3280-46	90 TABLET in 1 BOTTLE (0527-3280-46)

Profile for product number 001

Active Rx/OTC/Discontinued:	RX	Dosage:	TABLET;ORAL			Strength	0.025MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium
Approval Date:	Mar 1, 2002	TE:	AB1,AB2,AB3	RLD:	No

Profile for product number 002

Active Rx/OTC/Discontinued:	RX	Dosage:	TABLET;ORAL			Strength	0.05MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium
Approval Date:	Mar 1, 2002	TE:	AB1,AB2,AB3	RLD:	No

Profile for product number 003

Active Rx/OTC/Discontinued:	RX	Dosage:	TABLET;ORAL			Strength	0.075MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium
Approval Date:	Mar 1, 2002	TE:	AB1,AB2,AB3	RLD:	No

Expired US Patents for NDA 021342

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Cediprof Inc	LEVO-T	levothyroxine sodium	TABLET;ORAL	021342-010	Mar 1, 2002	6,399,101	⤷ Start Trial
Cediprof Inc	LEVO-T	levothyroxine sodium	TABLET;ORAL	021342-004	Mar 1, 2002	6,399,101	⤷ Start Trial
Cediprof Inc	LEVO-T	levothyroxine sodium	TABLET;ORAL	021342-008	Mar 1, 2002	6,399,101	⤷ Start Trial
Cediprof Inc	LEVO-T	levothyroxine sodium	TABLET;ORAL	021342-011	Mar 1, 2002	6,399,101	⤷ Start Trial
Cediprof Inc	LEVO-T	levothyroxine sodium	TABLET;ORAL	021342-001	Mar 1, 2002	6,399,101	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.